glp 1 for alcohol cravings GLP1 receptor agonists are supported by preclinical and observational evidence reducing addictive behaviors, particularly and nicotine use. Initial randomized clinical trials indicate possible reductions in craving and substance intake, though Semaglutide and Tirzepatide reduce alcohol

Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, Urva S, Haupt A, Robins DA

A separate randomised, double-blind, placebo-controlled trial in type 2 diabetic adults showed a significant increase in postprandial GLP-1 concentration following butyrate supplementation, with a decreasing trend in insulin resistance indices [3]

They work by mimicking a natural hormone that helps regulate appetite and promotes a feeling of fullness, making it easier to reduce calorie intake

Niazi explains that tirzepatide is a newer dual-agonist that targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which he says offers superior metabolic regulation and appetite suppression. Mounjaro is currently FDA-approved for type 2 diabetes, and Zepbound is also FDA-approved for weight loss

The library preparation and sequence analysis were performed by the Yale Center for Genome Analysis (YCGA), and our lab performed bioinformatics analysis